Brilliant Blue FCF (Acid Blue 9)
(Synonyms: 食用色素亮蓝,Acid Blue 9; FD&C Blue No. 1; E133) 目录号 : GC30036
亮蓝 FCF（酸性蓝 9）外观为红蓝色粉末。
Cas No.:3844-45-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Brilliant Blue FCF has the appearance of a reddish-blue powder. It is soluble in water, and the solution has a maximum absorption at about 628 nanometers. It is a synthetic dye produced using aromatic hydrocarbons from petroleum, is a colorant for foods and other substances.
| Cas No. | 3844-45-9 | SDF | |
| 别名 | 食用色素亮蓝,Acid Blue 9; FD&C Blue No. 1; E133 | ||
| Canonical SMILES | O=S(C1=CC(C/[N+](CC)=C2C=C/C(C=C/2)=C(C3=CC=C(N(CC)CC4=CC=CC(S(=O)([O-])=O)=C4)C=C3)\C5=CC=CC=C5S(=O)([O-])=O)=CC=C1)([O-])=O.[Na+].[Na+] | ||
| 分子式 | C37H34N2Na2O9S3 | 分子量 | 792.85 |
| 溶解度 | Water : ≥ 48 mg/mL (60.54 mM);Water : 33.33 mg/mL (42.04 mM; ultrasonic and adjust pH to 11 with NaOH) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2613 mL | 6.3064 mL | 12.6127 mL |
| 5 mM | 0.2523 mL | 1.2613 mL | 2.5225 mL |
| 10 mM | 0.1261 mL | 0.6306 mL | 1.2613 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Health safety issues of synthetic food colorants
Regul Toxicol Pharmacol 2015 Dec;73(3):914-22.26404013 10.1016/j.yrtph.2015.09.026
Increasing attention has been recently paid to the toxicity of additives used in food. The European Parliament and the Council published the REGULATION (EC) No. 1333/2008 on food additives establishing that the toxicity of food additives evaluated before 20th January 2009 must be re-evaluated by European Food Safety Authority (EFSA). The aim of this review is to survey current knowledge specifically on the toxicity issues of synthetic food colorants using official reports published by the EFSA and other available studies published since the respective report. Synthetic colorants described are Tartrazine, Quinoline Yellow, Sunset Yellow, Azorubine, Ponceau 4R, Erythrosine, Allura Red, Patent Blue, Indigo Carmine, Brilliant Blue FCF, Green S, Brilliant Black and Brown HT. Moreover, a summary of evidence on possible detrimental effects of colorant mixes on children's behaviour is provided and future research directions are outlined.
Brilliant Blue FCF is a nontoxic dye for saphenous vein graft marking that abrogates response to injury
J Vasc Surg 2016 Jul;64(1):210-8.25704409 PMC4544660
Background: Injury to saphenous vein grafts during surgical preparation may contribute to the subsequent development of intimal hyperplasia, the primary cause of graft failure. Surgical skin markers currently used for vascular marking contain gentian violet and isopropanol, which damage tissue and impair physiologic functions. Brilliant Blue FCF (FCF) is a nontoxic dye alternative that may also ameliorate preparation-induced injury. Methods: Porcine saphenous vein (PSV) was used to evaluate the effect of FCF on physiologic responses in a muscle bath. Cytotoxicity of FCF was measured using human umbilical venous smooth muscle cells. Effect of FCF on the development of intimal hyperplasia was evaluated in organ culture using PSV. Intracellular calcium fluxes and contractile responses were measured in response to agonists and inhibitors in rat aorta and human saphenous vein. Results: Marking with FCF did not impair smooth muscle contractile responses and restored stretch injury-induced loss in smooth muscle contractility of PSV. Gentian violet has cytotoxic effects on human umbilical venous smooth muscle cells, whereas FCF is nontoxic. FCF inhibited intimal thickening in PSV in organ culture. Contraction induced by 2'(3')-O-(4-benzoylbenzoyl)adenosine 5'-triphosphate and intracellular calcium flux were inhibited by FCF, oxidized adenosine triphosphate, KN-62, and brilliant blue G, suggesting that FCF may inhibit the purinergic receptor P2X7. Conclusions: Our studies indicated that FCF is a nontoxic marking dye for vein grafts that ameliorates vein graft injury and prevents intimal thickening, possibly due to P2X7 receptor inhibition. FCF represents a nontoxic alternative for vein graft marking and a potentially therapeutic approach to enhance outcome in autologous transplantation of human saphenous vein into the coronary and peripheral arterial circulation.
Determination of Brilliant Blue FCF by a Novel Solid-state ECL Quenching Sensor of Ru(bpy)32+-poly(sulfosalicylic acid)/GCE
Anal Sci 2017;33(10):1123-1128.28993585 10.2116/analsci.33.1123
A novel solid-state electrochemiluminescence (ECL) quenching sensor was constructed for determination of Brilliant Blue FCF (BB FCF). Under a simple electropolymerization step, poly(sulfosalicylic acid) (PSSA) film attached luminophore Ru(bpy)32+ was successfully formed on the surface of a glass carbon electrode [Ru(bpy)32+-PSSA/GCE], which exhibited excellent ECL behavior. A high quenching effect on the ECL signal of the Ru(bpy)32+-PSSA/GCE was obtained with the presence of low concentration of BB FCF. Moreover, the quenched ECL intensity showed a linear relation within the BB FCF concentration range of 0.5 - 7 and 7 - 10 μmol/L, with a detection limit of 57 nmol/L (S/N = 3). Besides, Ru(bpy)32+-PSSA/GCE exhibited good reproducibility and was successfully applied in the practical detection of BB FCF in peppermint candy samples.
Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia
J Vasc Surg 2016 Aug;64(2):471-478.27763268 PMC5480606
Background: Intimal hyperplasia remains the primary cause of vein graft failure for the 1 million yearly bypass procedures performed using human saphenous vein (HSV) grafts. This response to injury is caused in part by the harvest and preparation of the conduit. The use of Brilliant Blue FCF (FCF) restores injury-induced loss of function in vascular tissues possibly via inhibition of purinergic receptor signaling. This study investigated whether pretreatment of the vein graft with FCF prevents intimal hyperplasia. Methods: Cultured rat aortic smooth muscle cells (A7r5) were used to determine the effect of FCF on platelet-derived growth factor-mediated migration and proliferation, cellular processes that contribute to intimal hyperplasia. The effectiveness of FCF treatment during the time of explantation on preventing intimal hyperplasia was evaluated in a rabbit jugular-carotid interposition model and in an organ culture model using HSV. Results: FCF inhibited platelet-derived growth factor-induced migration and proliferation of A7r5 cells. Treatment with FCF at the time of vein graft explantation inhibited the subsequent development of intimal thickening in the rabbit model. Pretreatment with FCF also prevented intimal thickening of HSV in organ culture. Conclusions: Incorporation of FCF as a component of vein graft preparation at the time of explantation represents a potential therapeutic approach to mitigate intimal hyperplasia, reduce vein graft failure, and improve outcome of the autologous transplantation of HSV.
Active transport of Brilliant Blue FCF across the Drosophila midgut and Malpighian tubule epithelia
Comp Biochem Physiol A Mol Integr Physiol 2020 Jan;239:110588.31648063 10.1016/j.cbpa.2019.110588
Under conditions of stress, many animals suffer from epithelial barrier disruption that can cause molecules to leak down their concentration gradients, potentially causing a loss of organismal homeostasis, further injury or death. Drosophila is a common insect model, used to study barrier disruption related to aging, traumatic injury, or environmental stress. Net leak of a non-toxic dye (Brilliant Blue FCF) from the gut lumen to the hemolymph is often used to identify barrier failure under these conditions, but Drosophila are capable of actively transporting structurally-similar compounds. Here, we examined whether cold stress (like other stresses) causes Brilliant Blue FCF (BB-FCF) to appear in the hemolymph of flies fed the dye, and if so whether Drosophila are capable of clearing this dye from their body following chilling. Using in situ midgut leak and transport assays as well as Ramsay assays of Malpighian tubule transport, we tested whether these ionoregulatory epithelia can actively transport BB-FCF. In doing so, we found that the Drosophila midgut and Malpighian tubules can mobilize BB-FCF via an active transcellular pathway, suggesting that elevated concentrations of the dye in the hemolymph may occur from increased paracellular permeability, reduced transcellular clearance, or both. SUMMARY STATEMENT: Drosophila are able to actively secrete Brilliant Blue FCF, a commonly used marker of barrier dysfunction.